- Home
- LXRX
as 06-20-2025 4:00pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 228.8M | IPO Year: | 2000 |
| Target Price: | $3.67 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $2.45 | Next Earning Date: | 07-31-2025 |
| Revenue: | $31,213,000 | Revenue Growth: | 1251.21% |
| Revenue Growth (this year): | -44.11% | Revenue Growth (next year): | -26.80% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Zacks
19 days ago
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
Investopedia
22 days ago
Ulta Stock Jumps as Beauty Product Spending Continues
GlobeNewswire
22 days ago
Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
GlobeNewswire
22 days ago
Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
Benzinga
22 days ago
Northrop Grumman Raises $1 Billion Via Debt
GlobeNewswire
22 days ago
Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
Newsfile
22 days ago
Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.